Eisai Co Ltd (ESALF) 55.9074 $ESALF Eisai Highlights its

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Eisai Co Ltd (ESALF) 55.9074 $ESALF

Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day
PR Newswire - Wed Jun 29, 1:35PM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today held a Scientific Day to present its approach to global R&D and introduce the company's robust neurology and oncology pipeline, featuring innovative investigational assets being developed to address unmet medical needs. The meeting included presentations from members of Eisai's leadership, heads of research and development, and other key scientific leaders.

Eisai Enters into a Collaboration Agreement to Co-Promote LENVIMA® (Lenvatinib) in Combination with Everolimus in the U.S.
PR Newswire - Thu Jun 02, 3:15PM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Novartis Pharmaceuticals Corporation, an affiliate of Basel, Switzerland-based Novartis AG, have entered into an agreement to collaborate on commercial and medical affairs activities for LENVIMA® capsules in combination with everolimus in the United States for the treatment of patients with advanced renal cell carcinoma (aRCC), who were previously treated with an anti-angiogenic therapy.
NVS: 82.13 (+0.33)

Eisai to Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate)
JCN Newswire - Wed May 25, 6:38AM CDT


Maria Garrigan appointed Vice President, Global Regulatory Strategy, Oncology Business Group at Eisai Inc.
PR Newswire - Tue May 24, 7:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Maria Garrigan, as Vice President, Global Regulatory Strategy for the Oncology Business Group (OBG).

Eisai to Present New Research on Oncology Products and Pipeline at 52nd Asco Annual Meeting
JCN Newswire - Mon May 23, 8:36PM CDT
TOKYO, May 24, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that a series of abstracts highlighting new study results on Halaven (eribulin mesylate; halichondrin class microtubule dynamics inhibitor, "eribulin" and Lenvima (lenvatinib mesylate; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, "lenvatinib" will be presented during the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 3 to 7, 2016.

U.S. FDA Approves Additional Indication for Eisai's Anticancer Agent Lenvima in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma
JCN Newswire - Sun May 15, 10:44PM CDT
TOKYO, May 16, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. This is the only combination regimen to significantly prolong progression-free survival (PFS) when compared with a standard of care in patients with advanced renal cell carcinoma following prior anti-angiogenic therapy. Lenvima was designated as a Breakthrough Therapy by the FDA and also received a Priority Review, with approval obtained approximately six months after application submission.

Dr. Avinash Desai appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group at Eisai Inc.
PR Newswire - Wed Apr 20, 7:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Avinash Desai, MD, as Vice President, Americas Oncology Medical Affairs for the Oncology Business Group (OBG).

Beyhan Zaim appointed Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group at Eisai Inc.
PR Newswire - Mon Apr 11, 7:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Beyhan Zaim as Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group.

Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai Inc.
PR Newswire - Wed Apr 06, 7:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Paul Hawthorne to the position of Senior Vice President, U.S. Commercial, Neurology Business Group. In this role, Mr. Hawthorne will be responsible for leading the U.S. Neurology Sales and Marketing teams in bringing Eisai's neurology portfolio of products to patients.

Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of Advanced Liposarcoma
JCN Newswire - Mon Apr 04, 8:11PM CDT
TOKYO, Apr 5, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent Halaven (eribulin mesylate) for treatment of adult patients with unresectable liposarcomas who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease. Halaven is the first and only single agent to demonstrate an overall survival (OS) benefit in a Phase III trial in patients with advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). Following approval for use in the treatment of metastatic breast cancer in the EU, this marks the second indication for which Halaven has received a positive CHMP opinion based on a statistically significant extension of OS.

Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories
JCN Newswire - Thu Mar 31, 3:34AM CDT
TOKYO, Mar 31, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. (Dr. Reddy's).
RDY: 53.42 (+0.52)

Eisai's Notice Concerning Shelf Registration for Issuance of Stock Options
JCN Newswire - Wed Mar 30, 10:27PM CDT
TOKYO, Mar 30, 2016 - (JCN Newswire) - Eisai Co., Ltd. ("the Company" today filed a shelf registration statement with the Kanto Local Finance Bureau for issuance of stock options in accordance with the Company's "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" ("the Policy".This submission corresponds to the expiration of the previous shelf registration (period from April 7, 2014 to April 6, 2016) filed on March 28, 2014.

Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd.
JCN Newswire - Wed Mar 30, 9:35PM CDT


Eisai's Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016
JCN Newswire - Wed Mar 30, 9:35PM CDT
TOKYO, Mar 30, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016, as follows:

Global Drug Maker Eisai Signs Three-Year Contract Extension For CSC's Total Regulatory Solution (TRS) as-a-Service
BusinessWire - Wed Mar 30, 9:00AM CDT
CSC (NYSE: CSC), a global leader in next-generation IT services and solutions, announced today that Eisai Inc. has signed a three-year contract extension for CSC's Total Regulatory Solutions (TRS) as-a-Service. The agreement extends the ongoing life sciences software and cloud-hosting services CSC provides to Tokyo-based Eisai Co., Ltd.'s U.S. pharmaceutical subsidiary until December 2019.
CSC: 49.89 (+1.09)

Eisai's In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) Approved in Japan
JCN Newswire - Mon Mar 28, 10:07PM CDT


Eisai Withdraws New Drugs Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis
JCN Newswire - Tue Mar 22, 2:17AM CDT
TOKYO, Mar 22, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has withdrawn its new drug application for ultra-high dose Mecobalamin development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan.

Helsinn and Eisai Announce Revised U.S. Collaboration for CINV Franchise
PR Newswire - Fri Mar 18, 6:55AM CDT
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, and Eisai Inc., the U.S. pharmaceutical subsidiary of the research-based human healthcare company Eisai Co., Ltd , announced today a revised agreement for their chemotherapy-induced nausea and vomiting (CINV) franchise.

Notice Regarding Discontinuation of Sales and Voluntary Recall of Egg White Lysozyme Preparation Neuzym
JCN Newswire - Thu Mar 17, 7:11AM CDT


Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 85.54 (+2.01), IMGN: 3.16 (+0.04), ARQL: 1.69 (+0.03), LLY: 79.53 (+0.21), GSK: 43.50 (+0.16), ONTY: 1.21 (+0.02), MDVN: 62.71 (-0.03), MRK: 59.43 (+0.65), AZN: 30.21 (+0.10), AVEO: 0.95 (+0.02), GALE: 0.45 (-0.06), PBYI: 34.42 (+2.27), NVS: 82.13 (+0.33), KPTI: 7.18 (+0.08), XLRN: 34.35 (+0.44), EXEL: 8.14 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 371

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 130

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 100

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 488

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading

Top 5 Most Recently Viewed Articles

Kochav Defense Offers Class A Shares for Independent Trading

Updated Category News Views 100

Kochav Defense Initiates Separate Trading of Class A Shares Kochav Defense Acquisition Corp. (NASDAQ: KCHVU) has exciting news for its investors! Starting July 21, 2025, holders of the unit shares sold during its initial public offering will have the option to trade their Class A ordinary shares and rights separately. This development is expected to provide additional...

Continue Reading
CITGO Takes Active Steps in Community Safety Drills

Updated Category News Views 234

CITGO Lake Charles Refinery completed a significant emergency response drill back in 2024, engaging over 130 participants including local, state, and federal emergency responders. This Worst-Case scenario drill simulated operations on the waterway to bolster command capabilities during potential environmental incidents. Emergency Preparedness: The Core of CITGO's...

Continue Reading
Exploring Premium REITs for Reliable Cash Flow Generation

Updated Category News Views 196

Understanding High-Yield REIT Investments Investing in high-yield real estate investment trusts (REITs) is a popular strategy for those seeking attractive dividend income. REITs are uniquely designed to channel income back to their shareholders, making them an appealing choice for generating passive income streams. This article will explore several high-yield REITs that...

Continue Reading
Orchestra BioMed Strengthens Board with Industry Veteran

Updated Category News Views 180

Introduction of Christopher Cleary to the Orchestra BioMed Board Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is thrilled to announce a significant addition to its Board of Directors. Christopher Cleary, a monumental figure in the medical device industry, has joined the team as an independent member effective January 30, 2025. With over three decades of experience in...

Continue Reading
Microsoft's Latest Buyback Plan: What Investors Should Know

Updated Category News Views 202

Microsoft's Strategic Financial Moves Microsoft is making significant investments in its key areas while also ensuring it rewards its shareholders. As the tech giant ramps up its capital expenditures to improve cloud infrastructure—especially for artificial intelligence (AI)—it’s also keen on providing returns to its investors. Recently, the company announced a 10%...

Continue Reading